FDA Approved: ARRANON — Supplemental Application (Sandoz Inc)

View source ↗

Summary

The FDA approved Sandoz Inc.'s supplemental application for ARRANON (nelarabine), resulting in a labeling update for the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Acute Lymphoblastic Leukemia
• T-cell Lymphoblastic Lymphoma

Drugs mentioned

• ARRANON (nelarabine)

Snippet

SUPPL AP for ARRANON (NELARABINE)